Assignment Agreements in the Biotechnology Industry
166 Contracts & Agreements
- Acorda Therapeutics (3 contracts)
- Actinium Pharmaceuticals, Inc. (4)
- Adamas Pharmaceuticals Inc (1)
- ADiTx Therapeutics, Inc. (1)
- Adverum Biotechnologies, Inc. (2)
- Akebia Therapeutics, Inc. (1)
- Allarity Therapeutics, Inc. (1)
- Alliqua BioMedical, Inc. (1)
- AMARILLO BIOSCIENCES INC (1)
- Anixa Biosciences Inc (2)
- Aravive, Inc. (0)
- ARCA biopharma, Inc. (4)
- ATHERSYS, INC (1)
- Avid Bioservices, Inc. (1)
- BeiGene, Ltd. (1)
- BIOCEPT INC (5)
- BioRestorative Therapies, Inc. (1)
- bluebird bio, Inc. (1)
- BRAINSTORM CELL THERAPEUTICS INC. (1)
- Calyxt, Inc. (4)
- Capstone Therapeutics Corp. (1)
- Caribou Biosciences, Inc. (4)
- CASI Pharmaceuticals, Inc. (1)
- Cellular Biomedicine Group, Inc. (1)
- Centessa Pharmaceuticals Ltd (4)
- CEREBAIN BIOTECH CORP. (1)
- Checkpoint Therapeutics, Inc. (1)
- Cidara Therapeutics, Inc. (0)
- CLEVELAND BIOLABS INC (2)
- Constellation Alpha Capital Corp. (1)
- CYTRX CORP (1)
- DelMar Pharmaceuticals, Inc. (2)
- DYADIC INTERNATIONAL INC (2)
- Eiger BioPharmaceuticals, Inc. (1)
- Emerald Bioscience, Inc. (1)
- Flex Pharma, Inc. (2)
- HEAT BIOLOGICS, INC. (4)
- HISTOGENICS CORP (2)
- Homology Medicines, Inc. (1)
- IDERA PHARMACEUTICALS, INC. (1)
- IMMUNE PHARMACEUTICALS INC (1)
- Immune Therapeutics, Inc. (2)
- IMMUNOMEDICS INC (1)
- IN8BIO, INC. (0)
- InMed Pharmaceuticals Inc. (3)
- Inmune Bio, Inc. (1)
- Innovation Pharmaceuticals Inc. (6)
- Inspyr Therapeutics, Inc. (2)
- IO Biotech, Inc. (7)
- Lantern Pharma Inc. (1)
- MiMedx Group, Inc. (6)
- MIRAGEN THERAPEUTICS, INC. (2)
- Moleculin Biotech, Inc. (1)
- NantKwest, Inc. (2)
- Neurotrope, Inc. (1)
- Nuo Therapeutics, Inc. (1)
- Ohr Pharmaceutical Inc (1)
- OncBioMune Pharmaceuticals, Inc (2)
- Opko Health, Inc. (1)
- ORAGENICS INC (2)
- Orgenesis Inc. (1)
- Pfenex Inc. (2)
- POLARITYTE, INC. (1)
- Progenics Pharmaceuticals, Inc. (1)
- PROTEON THERAPEUTICS INC (2)
- ProtoKinetix, Inc. (1)
- Rasna Therapeutics Inc. (1)
- RenovaCare, Inc. (4)
- Rezolute, Inc. (1)
- Rich Pharmaceuticals, Inc. (4)
- SELLAS Life Sciences Group, Inc. (1)
- SOLENO THERAPEUTICS INC (1)
- Sorrento Therapeutics, Inc. (2)
- Spero Therapeutics, Inc. (1)
- SPHERIX INC (5)
- SUNESIS PHARMACEUTICALS INC (3)
- TENAX THERAPEUTICS, INC. (1)
- TG THERAPEUTICS, INC. (1)
- Tonix Pharmaceuticals Holding Corp. (1)
- U.S. Stem Cell, Inc. (7)
- Vaxcyte, Inc. (1)
- VBI Vaccines Inc (3)
- Xenetic Biosciences, Inc. (7)
- XOMA Corp (1)
- Y-mAbs Therapeutics, Inc. (1)
- Assignment Agreement dated as of December 11, 2023 (ADiTx Therapeutics, Inc., Filed With SEC on December 12, 2023)
- Assignment Agreement, dated October 10, 2023, by and between ABT Holding Company and HEALIOS K.K (ATHERSYS, INC, Filed With SEC on November 16, 2023)
- Consent to Assignment and First Amendment by and among ARE-San Francisco No. 63, LLC, Codexis, Inc. and the Registrant, dated September 6, 2023 (Vaxcyte, Inc., Filed With SEC on November 6, 2023)
- Employee Confidential Information and Inventions Assignment Agreement, dated October 17, 2023, between Michael Rossi and the Company (Y-mAbs Therapeutics, Inc., Filed With SEC on October 18, 2023)
- General Assignment for the Benefit of Creditors, dated as of August 16, 2023, by and between Aceragen, Inc. and ACG (ABC), LLC (IDERA PHARMACEUTICALS, INC., Filed With SEC on August 16, 2023)
- Assignment and Assumption Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation (XOMA Corp, Filed With SEC on August 8, 2023)
- Assignment and Assumption Agreement, dated June 21, 2023, by and between LadRx Corporation and XOMA (US) LLC (CYTRX CORP, Filed With SEC on June 26, 2023)
- Transfer and Assignment Agreement, dated May 3, 2022, by and between Cibus US LLC and Cibus Global, LLC (Calyxt, Inc., Filed With SEC on February 14, 2023)
- Transfer and Assignment Agreement, dated May 3, 2022, by and between Cibus Europe B.V. and Cibus Global, LLC (Calyxt, Inc., Filed With SEC on February 14, 2023)
- Contribution and Assignment Agreement, dated May 3, 2022, by and between Cibus Global, LLC and Cibus Charitable Foundation, Inc (Calyxt, Inc., Filed With SEC on February 14, 2023)
- Assignment Agreement, dated May 3, 2022, by and between Cibus Global, LLC and Cibus Charitable Foundation, Inc (Calyxt, Inc., Filed With SEC on February 14, 2023)
- Second Amendment to Assignment and Exclusive Cross-License Agreement with Aegea, dated May 22, 2022, by and between Biocept, Inc. and Aegea Biotechnologies (BIOCEPT INC, Filed With SEC on November 10, 2022)
- Assignment and Assumption Agreement between Allarity Therapeutics, Inc. and Allarity A/S (Allarity Therapeutics, Inc., Filed With SEC on May 17, 2022)
- Assignment and Assumption Agreement, dated March 10, 2022, between Homology Medicines, Inc. and Roadrunner Solutions LLC (Homology Medicines, Inc., Filed With SEC on March 23, 2022)
- Assignment and Assumption Agreement between Heat Biologics, Inc. and Pelican Therapeutics, Inc.(f/k/a Heat Biologics II, Inc.) dated June 26, 2009 (UM131-31, UM139) (HEAT BIOLOGICS, INC., Filed With SEC on March 11, 2022)
- Assignment and Assumption Agreement, dated February 24, 2022, by and between Keryx Biopharmaceuticals, Inc. and Akebia Therapeutics, Inc (Akebia Therapeutics, Inc., Filed With SEC on March 1, 2022)
- Assignment Agreement effective as of December 28, 2021 by and among the Registrant and Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P (SOLENO THERAPEUTICS INC, Filed With SEC on December 30, 2021)
- Assignment Consent Letter by and between WPD Pharmaceuticals Sp. z o.o and LPC Enterprises, LLC and Moleculin Biotech, Inc (Moleculin Biotech, Inc., Filed With SEC on December 27, 2021)
- 2nd Amendment to Option Assignment Agreement, dated as of December 7, 2018, by and between IO Biotech ApS and Herlev and Gentofte Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- 1st Amendment to Option Assignment Agreement, dated as of December 7, 2018, by and between IO Biotech ApS and Herlev and Gentofte Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- Option Assignment Agreement, dated as of March 27, 2017, by and between IO Biotech ApS and Herlev and Gentofte Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- Assignment Agreement, dated as of January 2, 2017, by and between IO Biotech ApS and Herlev and Gentofte Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- Framework Assignment Agreement, dated as of May 2, 2016, by and between IO Biotech ApS and Herlev Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- Addendum I to Option Assignment Agreement, dated as of May 2, 2016, by and between IO Biotech ApS and Herlev Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- Option Assignment Agreement, dated as of January 2, 2015, by and between IO Biotech ApS and Herlev Hospital (IO Biotech, Inc., Filed With SEC on October 26, 2021)
- Assignment Agreement for Patent Rights, dated July 1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz (ARCA biopharma, Inc., Filed With SEC on August 4, 2021)
- Amendment No. 3 to Sale and Assignment Agreement dated May 5, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 2 to Sale and Assignment Agreement dated as of December 15, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Amendment No. 1 to Sale and Assignment Agreement dated as of October 20, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Sale and Assignment Agreement, dated as of January 31, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)
- Assignment Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH (Anixa Biosciences Inc, Filed With SEC on June 10, 2021)
- Assignment and Bill of Sale, dated December 20, 2017, by and between Advent Private Equity Fund III A, Advent Private Equity Fund III B, Palladio Biosciences, Inc and the other... (Centessa Pharmaceuticals Ltd, Filed With SEC on May 12, 2021)
- Assignment and Bill of Sale, dated November 7, 2017, by and between Healthcare Ventures VII, L.P., and Palladio Biosciences, Inc (Centessa Pharmaceuticals Ltd, Filed With SEC on May 12, 2021)
- Assignment and Bill of Sale, dated June 2017, by and between Perseus-Soros BioPharmaceutical Fund Liquidating Trust and Palladio Biosciences, Inc (Centessa Pharmaceuticals Ltd, Filed With SEC on May 12, 2021)
- Assignment and Bill of Sale, dated February 24, 2017, by and between Care Capital Investments II, LP, Care Capital Offshore Investments II, LP, and Palladio Biosciences, Inc (Centessa Pharmaceuticals Ltd, Filed With SEC on May 12, 2021)
- Patent Assignment, dated April 15, 2021, by Ainos, Inc (AMARILLO BIOSCIENCES INC, Filed With SEC on April 21, 2021)
- Amendment to the Assignment Agreement, dated February 14, 2013, by and among SciGen Ltd., SciGen (I.L.) Ltd (VBI Vaccines Inc, Filed With SEC on March 2, 2021)
- Assignment Agreement, dated October 16, 2012, by and among FDS Pharma LLP, SciGen Ltd., and SciGen (I.L.) Ltd (VBI Vaccines Inc, Filed With SEC on March 2, 2021)
- Assignment Agreement, dated February 14, 2012, between FDS Pharma LLP and SciGen Ltd (VBI Vaccines Inc, Filed With SEC on March 2, 2021)
- Assignment Agreement, dated July 2, 2017, by and between NantPharma, LLC and Immunotherapy NANTibody, LLC (NantKwest, Inc., Filed With SEC on January 19, 2021)
